Tafluprost/timolol now available as combined glaucoma treatment

Taptiqom is a fixed-dose combination of the prostaglandin analogue tafluprost and the beta-blocker timolol, for the treatment of glaucoma.

The recommended dose of Taptiqom is one drop into the affected eye(s) once daily. | iStock
The recommended dose of Taptiqom is one drop into the affected eye(s) once daily. | iStock

Taptiqom is indicated for the reduction of intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta blockers or prostaglandin analogues and require a combination therapy. It is presented as preservative-free eye drops in single-dose containers.

Tafluprost and timolol reduce intraocular pressure by complementary mechanisms of action.

IOP reduction

Further information
View Taptiqom drug record 
Summary of Product Characteristics
Manufacturer: Santen UK

Two 6-month, randomised, double-blind, phase III studies compared the safety and efficacy of the preservative-free fixed combination of tafluprost 15 microgram/ml and timolol 5mg/ml with those of the two drugs as single agents or as a non-fixed combination in patients with open-angle glaucoma or ocular hypertension.

In the first study (n=400), mean diurnal IOP decreases from baseline ranged from -7.3 to -9.1 mmHg (29.6–34.6%) with the fixed combination and from -7.5 to -9.4 mmHg (30.7–36.0%) with the non-fixed combination (p<0.0001 vs="" baseline="" for="" both="" an="" iop="" decrease="" of="" at="" least="" 30="" was="" achieved="" in="" 58="" 3="" and="" 66="" 9="" the="" patients="" fixed-combination="" non-fixed-combination="" groups="" respectively="" p="" all="" measures="" reduction="" fixed="" tafluprost="" timolol="" combination="" were="" statistically="" clinically="" significant="" non-inferior="" to="" those="" non-fixed="">

In the second study, 564 patients whose condition was inadequately controlled on timolol or prostaglandin monotherapy for 6 months received timolol, tafluprost or the fixed tafluprost/timolol combination.

Average diurnal IOP change from baseline at month 3 was 32–33% for patients who received the combination, 28% for those treated with timolol and 28% for those who received tafluprost. The treatment difference was significant for the combination versus both timolol (p=0.044) and tafluprost (p<0.001), indicating superiority to both monotherapies.


The most common adverse effect of the tafluprost/timolol combination was conjunctival hyperaemia, which occcured in approximately 7% of patients.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases